Regarding new therapeutic approaches, emerging treatments such as dipeptidyl peptidase 1 (DPP1) inhibitors, along with other anti-inflammatory and host-directed strategies, have been tested almost exclusively in populations without overt immunodeficiency [83,84]. This evidence concerns the gene CTSC and immunodeficiency disease.